nach oben

Erschienen in:

01.05.2012 | Original paper

Association of colorectal adenoma with components of metabolic syndrome

verfasst von: Byung Chang Kim, Aesun Shin, Chang Won Hong, Dae Kyung Sohn, Kyung Su Han, Kum Hei Ryu, Bum Joon Park, Ji Hyung Nam, Ji Won Park, Hee Jin Chang, Hyo Seong Choi, Jeongseon Kim, Jae Hwan Oh

Erschienen in: Cancer Causes & Control | Ausgabe 5/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recently, some studies have shown that diabetes mellitus and metabolic syndrome increase the risk of colorectal neoplasms. Although the mechanism is not known, those have been proposed to contribute to this phenomenon, including insulin resistance, oxidative stress, and adipokine production. The objective of this study was to assess the association between metabolic risk factors and colorectal neoplasm.

Methods

Study participants visited the National Cancer Center, Korea, for screening (2007–2009). A total of 1,771 diagnosed adenoma patients and 4,667 polyp-free controls were included. The association between risk factors and colorectal neoplasm was evaluated using logistic regression models.

Results

High waist circumference, blood pressure, and serum triglyceride levels were associated with an increased risk of colorectal adenoma. Metabolic syndrome (MS) was associated with an increased risk of adenoma (OR = 1.44, 95 % CI = 1.23–1.70). The association between MS and colorectal adenoma was observed regardless of advanced/low-risk adenoma, and multiplicity. MS affected right colon adenomas (OR = 1.50, 95 % CI = 1.22–1.85), left colon adenomas (OR = 1.36, 95 % CI = 1.05–1.76), and adenomas in multiple anatomical locations (OR = 1.59, 95 % CI = 1.19–2.12), but was not associated with rectum.

Conclusion

Central obesity, triglyceride level, and MS are risk factors for colorectal adenoma including advanced adenoma and multiplicity.

Nur mit Berechtigung zugänglich

Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef

Jung KW, Park S, Kong HJ et al (2010) Cancer statistics in Korea: incidence, mortality and survival in 2006–2007. J Korean Med Sci 25:1113–1121PubMedCrossRef

Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedCrossRef

Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 329:1977–1981PubMedCrossRef

Lieberman DA, Weiss DG, Bond JH, Ahnen DJ, Garewal H, Chejfec G (2000) Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 343:162–168PubMedCrossRef

Chiu HM, Lin JT, Shun CT et al (2007) Association of metabolic syndrome with proximal and synchronous colorectal neoplasm. Clin Gastroenterol Hepatol 5:221–229PubMedCrossRef

Limburg PJ, Anderson KE, Johnson TW et al (2005) Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women’s Health Study. Cancer Epidemiol Biomarkers Prev 14:133–137PubMed

Slattery ML, Benson J, Berry TD et al (1997) Dietary sugar and colon cancer. Cancer Epidemiol Biomarkers Prev 6:677–685PubMed

Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21:215–244PubMedCrossRef

10.

Prisco M, Romano G, Peruzzi F, Valentinis B, Baserga R (1999) Insulin and IGF-I receptors signaling in protection from apoptosis. Horm Metab Res 31:80–89PubMedCrossRef

11.

Ma J, Pollak MN, Giovannucci E et al (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91:620–625PubMedCrossRef

12.

Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR (2006) The metabolic syndrome and risk of incident colorectal cancer. Cancer 107:28–36PubMedCrossRef

13.

Murphy TK, Calle EE, Rodriguez C, Kahn HS, Thun MJ (2000) Body mass index and colon cancer mortality in a large prospective study. Am J Epidemiol 152:847–854PubMedCrossRef

14.

Wang YY, Lin SY, Lai WA, Liu PH, Sheu WH (2005) Association between adenomas of rectosigmoid colon and metabolic syndrome features in a Chinese population. J Gastroenterol Hepatol 20:1410–1415PubMedCrossRef

15.

Morita T, Tabata S, Mineshita M, Mizoue T, Moore MA, Kono S (2005) The metabolic syndrome is associated with increased risk of colorectal adenoma development: the Self-Defense Forces health study. Asian Pac J Cancer Prev 6:485–489PubMed

16.

Kim JH, Lim YJ, Kim YH et al (2007) Is metabolic syndrome a risk factor for colorectal adenoma? Cancer Epidemiol Biomarkers Prev 16:1543–1546PubMedCrossRef

17.

Bowers K, Albanes D, Limburg P et al (2006) A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 164:652–664PubMedCrossRef

18.

Nam SY, Kim BC, Han KS et al (2010) Abdominal visceral adipose tissue predicts risk of colorectal adenoma in both sexes. Clin Gastroenterol Hepatol 8(443–50):e1–e2PubMed

19.

Pelucchi C, Negri E, Talamini R et al (2010) Metabolic syndrome is associated with colorectal cancer in men. Eur J Cancer 46:1866–1872PubMedCrossRef

20.

Shin A, Hong CW, Sohn DK, et al (2011) Associations of cigarette smoking and alcohol consumption with advanced or multiple colorectal adenoma risks: a colonoscopy-based case-control study in Korea. Am J Epidemiol 174:552–562

21.

Dixon MF (2002) Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 51:130–131PubMedCrossRef

22.

Hamilton SR, Aaltonen LA (2000) Pathology and genetics of tumours of the digestive system. IARC Press/Oxford University Press, Lyon/Oxford [distributor]

23.

Morois S, Mesrine S, Besemer F, Josset M, Clavel-Chapelon F, Boutron-Ruault MC (2011) Risks of colon and rectal adenomas are differentially associated with anthropometry throughout life: the French E3N prospective cohort. Int J Epidemiol 40:1269–1279

24.

Morois S, Mesrine S, Josset M, Clavel-Chapelon F, Boutron-Ruault MC (2010) Anthropometric factors in adulthood and risk of colorectal adenomas: The French E3N-EPIC prospective cohort. Am J Epidemiol 172:1166–1180PubMedCrossRef

25.

Region W (2000) IASO and IOTF: the Asia-Pacific perspective: redefining obesity and its treatment. Health Communications Australia Pty Limit., Sydney

26.

Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V (2003) Metabolic syndrome in urban Asian Indian adults—a population study using modified ATP III criteria. Diabetes Res Clin Pract 60:199–204PubMedCrossRef

27.

Liu CS, Hsu HS, Li CI et al (2010) Central obesity and atherogenic dyslipidemia in metabolic syndrome are associated with increased risk for colorectal adenoma in a Chinese population. BMC Gastroenterol 10:51PubMedCrossRef

28.

Tsilidis KK, Brancati FL, Pollak MN et al (2010) Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 21:1–10PubMedCrossRef

29.

Frezza EE, Wachtel MS, Chiriva-Internati M (2006) Influence of obesity on the risk of developing colon cancer. Gut 55:285–291PubMedCrossRef

30.

Gunter MJ, Hoover DR, Yu H et al (2008) Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 68:329–337PubMedCrossRef

31.

Giorgino F, Laviola L, Eriksson JW (2005) Regional differences of insulin action in adipose tissue: insights from in vivo and in vitro studies. Acta Physiol Scand 183:13–30PubMedCrossRef

32.

Cowey S, Hardy RW (2006) The metabolic syndrome: a high-risk state for cancer? Am J Pathol 169:1505–1522PubMedCrossRef

33.

Trayhurn P, Beattie JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60:329–339PubMedCrossRef

34.

Trayhurn P, Wood IS (2004) Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 92:347–355PubMedCrossRef

35.

Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL (2009) Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 15:5141–5148PubMedCrossRef

36.

Park HS, Kim SM, Lee JS et al (2007) Prevalence and trends of metabolic syndrome in Korea: Korean National Health and Nutrition Survey 1998–2001. Diabetes Obes Metab 9:50–58PubMedCrossRef

37.

Choe JW, Chang HS, Yang SK et al (2007) Screening colonoscopy in asymptomatic average-risk Koreans: analysis in relation to age and sex. J Gastroenterol Hepatol 22:1003–1008PubMedCrossRef

38.

Chung SJ, Kim YS, Yang SY et al (2010) Prevalence and risk of colorectal adenoma in asymptomatic Koreans aged 40–49 years undergoing screening colonoscopy. J Gastroenterol Hepatol 25:519–525PubMedCrossRef

Titel: Association of colorectal adenoma with components of metabolic syndrome
verfasst von: Byung Chang Kim
Aesun Shin
Chang Won Hong
Dae Kyung Sohn
Kyung Su Han
Kum Hei Ryu
Bum Joon Park
Ji Hyung Nam
Ji Won Park
Hee Jin Chang
Hyo Seong Choi
Jeongseon Kim
Jae Hwan Oh
Publikationsdatum: 01.05.2012
Verlag: Springer Netherlands
Erschienen in: Cancer Causes & Control / Ausgabe 5/2012
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-012-9942-9

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Association of colorectal adenoma with components of metabolic syndrome